Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

MKC8866 is an inhibitor of inositol-requiring enzyme 1α (IRE1α) RNase activity (IC50 = 0.29 µM).1 It inhibits DTT-induced production of the IRE1α target protein and transcription factor X-box binding protein 1 (XBP1) in MM.1S multiple myeloma cells (EC50 = 0.52 µM) and XBP1 production induced by thapsigargin (Item No. 10522) in LNCaP cells (IC50 = 0.38 µM). MKC8866 also decreases expression of the XBP1 target genes SREBF1, DGAT2, and LIPE and increases triglyceride levels in MDA-MB-231 cells.2 In vivo, MKC8866 (300 mg/kg) reduces tumor volume in LNCaP, VCaP, 22Rv1, and C4-2B prostate cancer mouse xenograft models.1
WARNING This product is not for human or veterinary use.
1. IRE1α-
2. Regulated IRE1α-